A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.
A cancer patient’s comorbid diseases have important implications for setting goals and selecting treatment, said Joseph Alvarnas, MD, of the City of Hope and editor-in-chief of Evidence-Based Oncology. Clinicians must keep comorbidities in mind as they base oncology care upon that person as an individual.
Transcript (slightly modified)
How do comorbidities impact outcomes in cancer patients?
One of the things that’s clear is that the selection of care, ranging from the goals of care and the scope of care and the therapeutics that might be chosen, have to be based upon that person as an individual. As the population ages, and as people with cancer age, the issue of multiple comorbidities — diabetes, hypertension, coronary artery disease, renal failure, things which we know are part of that patient’s experience independent of cancer – does have very important implications in treatment decisions, in the selection of different types of therapeutics based upon those comorbidities. As well as the strategy of care, how best to manage that individual and how best to create goals which are really realistic in light of their full complexity.
So I think when we think about value-based care, and goals of care, and the focus of care, we’re really talking about individualizing treatments in ways that extend beyond genetics and genomics and proteomics, to really understanding the full breadth of that person’s health prior to the advent of cancer, and seeing how that really has an inextricable influence upon the care decisions that follow thereafter.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More